Global Virus Network

Name

Global Virus Network

Legal name

Global Virus Network

Website

https://gvn.org

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Global Virus Network (GVN) is a non-profit coalition coordinating 90+ virology Centers of Excellence across 40+ countries, dedicated to pandemic preparedness, viral surveillance, outbreak response, and training the next generation of virologists through research, education, and institutional partnerships.

Ownership category

akta.pro rank

Product category

Virology Research Collaboration & Pandemic Preparedness

NAICS

Civic and Social Organizations (813410), International Affairs (92812)

SIC

Services-Membership Organizations (8600)

akta.pro industry

PRIMARYHLAJAOAH

Global Health Security & Pandemic Preparedness Partnerships

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health Initiatives & Partnerships

SECONDARYHLAJAIAE

Emerging Pathogen & Outbreak Response Testing Networks

Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks

SECONDARYHLAJAOAF

Immunization & Vaccine Access Partnerships (Global Vaccine Alliances)

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health Initiatives & Partnerships

Keywords

• Virology research collaboration
• Pandemic preparedness programs
• Viral surveillance research
• Infectious disease training
• Global health coalition

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Grant Funding and Philanthropic Support: As a non-profit 501(c)(3) organization, GVN operates through grant funding and philanthropic support. The organization awards pandemic preparedness research grants to scientists across multiple continents (e.g., $160,000 awarded in November 2025 to researchers across four continents). Revenue is derived from institutional partnerships, grants, and donations rather than commercial product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Global Virus Network (GVN) is a worldwide coalition of 90+ virology Centers of Excellence and Affiliates across 40+ countries that coordinates collaborative research, training, and pandemic preparedness initiatives. The organization delivers educational programs (webinars, short courses, mentorship), administers research grants, organizes international scientific meetings, and supports outbreak surveillance and response. GVN operates as a non-profit 501(c)(3) rather than a product vendor.

Product overview

The Global Virus Network (GVN) is a worldwide coalition comprising 90+ Virology Centers of Excellence and Affiliates across 40+ countries. Rather than a single product, GVN offers a portfolio of programs and services focused on pandemic preparedness: educational offerings including the Forefront of Virology Webinar Series and Global Guardians High School Summer Program; research programs such as multi-country mpox diagnostic evaluations and pandemic preparedness grants; training initiatives including the Short Course in Translational Virology and Rising Star Mentorship Program; and annual scientific meetings. These offerings work together to advance viral research, foster next-generation virology leaders, and enhance global resources for readiness and response to emerging viral threats.

Differentiator

Problem solved

Functional benefit

Products and services

• Forefront of Virology Webinar Series

Quantifiable outcome

• Over 4.4 million deaths prevented globally each year through vaccination, which GVN supports through its pandemic preparedness mission
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Nine partnerships are on record, tiered core and flagship.

• Coalition for Epidemic Preparedness Innovations (CEPI)coreStrategic or Co-development Partner · 27 April 2026CEPI supports the Phase 3 clinical trial of Moderna's mRNA-based H5N1 vaccine candidate (mRNA-1018). GVN has highlighted this as an important step in global preparedness, building on its prior Lancet analysis recommending accelerated vaccine development alongside strengthened surveillance.
• Tampa General Hospital (TGH) Cancer InstitutecoreStrategic or Co-development Partner · 2 March 2026GVN co-hosted the 'Microbes, Genes & Cancer' Symposium with TGH Cancer Institute and USF Health Morsani College of Medicine in Tampa on March 2-3, 2026. This event marked the 50th anniversary of IL-2 discovery and covered HPV-related cancers, hepatitis-associated liver cancer, HIV-related comorbidities, and tumor-microbiome interactions.
• University of St AndrewscoreStrategic or Co-development Partner · 25 September 2025GVN's multi-country mpox diagnostic evaluation includes Dr. Wilber Sabiiti from University of St Andrews spearheading validation efforts in DRC and Uganda. Study compares rapid antigen tests against gold-standard PCR assays in resource-limited settings.
• Duke University School of MedicinecoreStrategic or Co-development Partner · 4 February 2025Duke University School of Medicine joined GVN as a Center of Excellence in February 2025, bringing the Duke Human Vaccine Institute's cutting-edge vaccine research capabilities against HIV-1, influenza, SARS-CoV-2, tuberculosis, syphilis, and gonorrhea.
• National Institute of Virology and Bacteriology (NIVB) - Czech RepubliccoreStrategic or Co-development Partner · 4 February 2025NIVB joined GVN as a Center of Excellence in February 2025, bringing together top Czech research institutes funded by EU's NextGenerationEU program to accelerate development of drugs and vaccines against viral and bacterial pandemic threats.
• Yale UniversitycoreStrategic or Co-development Partner · 4 February 2025Yale University became a GVN Center of Excellence in February 2025, co-led by virologists in epidemiology, immunobiology, pediatrics, and laboratory medicine committed to collaborative research on viral disease prevention and control.
• University of Pennsylvania Perelman School of MedicinecoreStrategic or Co-development Partner · 4 February 2025Penn's Perelman School of Medicine joined GVN as a Center of Excellence in February 2025, bringing expertise in coronavirus research, MERS-CoV spillover studies, and home to the Penn Center for Research on Coronaviruses and Other Emerging Pathogens.
• University of South Florida (USF)flagshipStrategic or Co-development Partner · 5 June 2024USF hosts GVN's International Headquarters at the USF Health Institute for Translational Virology and Innovation (ITVI). This is GVN's most significant partnership, announced in June 2024 and officially opened March 5, 2026. Dr. Robert Gallo serves as James P. Cullison Professor of Medicine at USF and director of the ITVI. Dr. Sten Vermund serves as dean of USF Health College of Public Health and GVN's chief medical officer.
• Abbott LaboratoriescoreStrategic or Co-development Partner · 6 April 2022GVN and Abbott launched the Pandemic Defense Postdoctoral Fellowship Program in April 2022, training the next generation of virologists to combat future pandemic threats with focus on pathogen discovery in developing nations. Abbott serves as Corporate Partner. Gavin Cloherty, PhD leads Abbott's involvement.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• World Health Organization (WHO): WHO is the UN's global public health authority coordinating international outbreak response, surveillance, and pandemic preparedness. It is a broader incumbent operating across all health domains; GVN frequently partners with and is positioned alongside WHO in outbreak briefings, making it the most prominent institutional peer for GVN's mission.
• Africa Centres for Disease Control and Prevention (Africa CDC): Africa CDC is the continental public health agency coordinating surveillance, preparedness, and outbreak response across African Union member states. As a larger, government-backed incumbent with overlapping outbreak-response and capacity-building mandates, it is a key institutional peer and partner for GVN's African Centers of Excellence.

Direct peers

• Institut Pasteur International Network: The Institut Pasteur International Network is a global federation of 32+ research institutes across five continents dedicated to infectious disease research and outbreak response. It directly overlaps GVN's virology Centers-of-Excellence model and shares senior leadership lineage (GVN board vice chair Bréchot is a former Institut Pasteur president).
• Foundation for Innovative New Diagnostics (FIND): FIND is a global non-profit accelerating the development and deployment of diagnostic tests, including for outbreak-prone infectious diseases. Its diagnostic-evaluation and access mandate aligns closely with GVN's multi-country mpox diagnostic evaluation and broader surveillance/early-detection agenda.
• Coalition for Epidemic Preparedness Innovations (CEPI): CEPI is a global coalition that finances and coordinates vaccine development against epidemic threats, with a mission and stakeholder base (governments, multilaterals, industry, scientists) directly comparable to GVN's pandemic preparedness mandate. Both operate as multi-stakeholder coalitions advancing preparedness research across viral families and collaborate on initiatives like Moderna's H5N1 mRNA-1018 trial.
• Gavi, the Vaccine Alliance: Gavi is a public-private global health alliance that accelerates vaccine access and immunization in lower-income countries. Like GVN, it is coalition-based, mission-driven around viral threats, and partners with WHO, governments, and industry; its scale and immunization focus make it a natural peer for GVN's pandemic preparedness and vaccine advocacy work.

Others

• Bill & Melinda Gates Foundation: The Gates Foundation is a leading philanthropic funder of global health, immunization, and pandemic preparedness initiatives. While not a coalition peer, it is a primary source of comparable funding and a frequent partner of GVN-adjacent organizations like Gavi and CEPI.
• International Science Council: The International Science Council is a global non-governmental organization that convenes scientific bodies and mobilizes the scientific community on issues including health emergencies. It is an adjacent, ecosystem-level peer to GVN's role as a scientific convening body for virology.
• Wellcome Trust: Wellcome is a major global charitable foundation funding biomedical research and pandemic preparedness, including infectious disease surveillance and capacity building. As a likely donor and aligned funder, Wellcome is a key ecosystem participant comparable to GVN's philanthropic support base.

Emerging players

• International AIDS Society (IAS): IAS is a professional society convening HIV/AIDS researchers, clinicians, and policymakers through global conferences and capacity-building programs. GVN has deep HIV-research roots through its founders (Gallo co-discovered HIV) and HIV-focused Centers of Excellence, making IAS a closely adjacent peer in convening and scientific community-building.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/GlobalVirusNews

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Virus Network